Princeton Capital Management’s AstraZeneca AZN Stock Holding History

Princeton Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.94M	Buy	15,592 +2,513	+19%	+$473K	0.66%	28
2026 Q1	$2.56M	Buy	13,079 +1,570	+14%	+$303K	0.7%	26
2025 Q4	$2.12M	Buy	+11,509	New	+$2.02M	0.55%	31
2018 Q3	–	Sell	-141	Closed	-$10K	–	264
2018 Q2	$10K	Sell	141 -69	-33%	-$4.96K	﹤0.01%	248
2018 Q1	$15K	Buy	+210	New	+$14.5K	0.01%	228

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Princeton Capital Management's AZN Position: Q2 2026 in Review

Princeton Capital Management increased its AstraZeneca (AZN) stake by 19% in Q2 2026, buying an estimated $473K and bringing the position to 15,592 shares worth $2.94M. The position accounts for 0.66% of the portfolio, ranked #28.

Princeton Capital Management first reported a position in AZN in Q1 2018 and has held it in 5 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Princeton Capital Management held 15,592 shares of AstraZeneca worth $2.94M as of Q2 2026.
Princeton Capital Management bought 2,513 AstraZeneca shares in Q2 2026, an estimated $473K.
AstraZeneca made up 0.66% of Princeton Capital Management's portfolio in Q2 2026, its #28 holding.
Princeton Capital Management first reported a position in AstraZeneca in Q1 2018 and has held it in 5 quarters since.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Princeton Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.